NSI-189: Final Phase Ib data

Final data from a double-blind, U.S. Phase Ib trial in 24 patients with recurrent MDD showed that once- and twice-daily 40 mg oral NSI-189 led to “clinically meaningful” improvements in Montgomery-Asb...